- In a conference call with reporters, attorneys representing Sanofi (SNY +0.2%) in it and Regeneron's (REGN +0.8%) patent dispute with Amgen (AMGN) stated that a decision from the appeals court could happen at any time between June and December. In addition to reversing/affirming the district court decision, the case may be remanded back to the trial court.
- If Amgen's Repatha patent claims are upheld and the Praluent sales ban overturned, then Sanofi and Regeneron may have to pay royalties. The companies could appeal to the U.S. Supreme Court, if necessary.
- They also asserted that the public interest factor "will weigh heavily in our favor" throughout the process.
- Source: Bloomberg First Word